Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 729139105 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Tang Capital Management LLC
13D
|
9.6% |
3/10/2025
Event 3/3/2025
|
||
| Tang Capital Management, LLC | 9.6% | |||
| Kevin Tang | 9.6% | |||
| Tang Capital Partners, LP | 5.4% | |||
| Tang Capital Partners International, LP | 4.2% | |||
| Tang Capital Partners III, Inc | 0% | |||
| Tang Capital Partners IV, Inc | 0% | |||
| Concentra Biosciences, LLC | 0% | |||
|
ADAR1 Capital Management, LLC
13G
|
8.9% |
8/14/2026
Event 6/30/2026
|
||
| ADAR1 Capital Management, LLC | 8.9% | |||
| Daniel Schneeberger | 8.9% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (11) | ||||
| Vanguard Group Inc 13G/A | 4.9% |
7/29/2025
Event 6/30/2025
|
||
|
Redmile Group, LLC
13G/A
|
4.8% |
2/14/2025
Event 12/31/2024
|
||
| Redmile Group, LLC | 4.8% | |||
| Jeremy C. Green | 4.8% | |||
|
Citadel Advisors LLC
13G/A
|
3.5% |
8/14/2026
Event 6/30/2026
|
||
| Citadel Advisors LLC | 2.3% | |||
| Citadel Advisors Holdings LP | 2.3% | |||
| Citadel GP LLC | 2.3% | |||
| Citadel Securities LLC | 1.1% | |||
| Citadel Securities Group LP | 1.2% | |||
| Citadel Securities GP LLC | 1.2% | |||
| Kenneth Griffin | 3.5% | |||
| BlackRock, Inc. 13G/A | 3.4% |
7/17/2025
Event 6/30/2025
|
||
| Woodline Partners LP 13G/A | 3.3% |
2/17/2026
Event 12/31/2025
|
||
| Morgan Stanley 13G/A | 0.9% |
1/8/2026
Event 12/31/2025
|
||
|
FMR LLC
13G/A
|
0.2% |
3/7/2025
Event 2/28/2025
|
||
| FMR LLC | 0.2% | |||
| Abigail P. Johnson | 0.2% | |||
| Price T Rowe Associates Inc /MD/ 13G/A | 0.1% |
5/14/2025
Event 3/31/2025
|
||
|
Point72 Asset Management, L.P.
13G/A
|
0.1% |
2/17/2026
Event 12/31/2025
|
||
| Point72 Asset Management, L.P. | 0.1% | |||
| Point72 Capital Advisors, Inc. | 0.1% | |||
| Steven A. Cohen | 0.1% | |||
|
Deep Track Capital, LP
13G/A
|
0% |
11/14/2025
Event 9/30/2025
|
||
| Deep Track Capital, LP | 0% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | |||
| David Kroin | 0% | |||
|
Paradigm Biocapital Advisors LP
13G/A
|
0% |
5/15/2025
Event 3/31/2025
|
||
| Paradigm BioCapital Advisors LP | 0% | |||
| Paradigm BioCapital Advisors GP LLC | 0% | |||
| Senai Asefaw, M.D. | 0% | |||
| Paradigm BioCapital International Fund Ltd. | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 5.00 | $5.00 |
| 2026 Q2 | 89 | 48.1 M | $54.8 M |
| 2026 Q1 | 96 | 50.0 M | $62.9 M |
| 2025 Q4 | 104 | 47.1 M | $58.0 M |
| 2025 Q3 | 106 | 52.7 M | $78.0 M |
| 2025 Q2 | 120 | 51.5 M | $59.8 M |
| 2025 Q1 | 147 | 57.9 M | $78.5 M |
| 2024 Q4 | 169 | 64.8 M | $851 M |
| 2024 Q3 | 164 | 63.7 M | $727 M |
| 2024 Q2 | 157 | 65.0 M | $698 M |
| 2024 Q1 | 148 | 66.2 M | $986 M |
| 2023 Q4 | 149 | 63.9 M | $1.16 B |
| 2023 Q3 | 146 | 60.2 M | $1.04 B |
| 2023 Q2 | 157 | 58.5 M | $1.06 B |
| 2023 Q1 | 155 | 57.7 M | $1.53 B |
| 2022 Q4 | 136 | 45.5 M | $879 M |
| 2022 Q3 | 118 | 45.7 M | $954 M |
| 2022 Q2 | 97 | 30.5 M | $244 M |
| 2022 Q1 | 95 | 32.0 M | $225 M |
| 2021 Q4 | 95 | 30.9 M | $417 M |
| 2021 Q3 | 80 | 30.4 M | $513 M |
| 2021 Q2 | 82 | 30.7 M | $894 M |
| 2021 Q1 | 77 | 30.7 M | $1.21 B |
| 2020 Q4 | 63 | 28.5 M | $648 M |
| 2020 Q3 | 56 | 28.2 M | $636 M |
| 2020 Q2 | 38 | 27.3 M | $877 M |